23 results
Thumbnail

D1.259 - Healthcare interoperability: the promises and pitfalls relating to penicillin allergy delabelling

Thumbnail

D1.250 - Beyond the Label: A Multidisciplinary Effort to De-label Penicillin Allergy

Thumbnail

D1.251 - Documentation of drug allergy in the Electronic Health Record (EHR) at a Tertiary paediatric allergy service in the UK

Thumbnail

D1.252 - A model based economic evaluation to assess impact of Penicillin Allergy in COPD patients

Thumbnail

D1.253 - Comparison of Immune-Related Adverse Events in Patients Treated with Atezolizumab and Durvalumab: A Critical Concern for Clinical Management

Thumbnail

D1.254 - Assessing the Accuracy of Penicillin Allergy Labels in Paediatric Care: Focusing on Educational Gaps in Both Families and Healthcare Workers

Thumbnail

D1.255 - Validation of the English Version of the Drug Hypersensitivity Quality of Life Questionnaire (DrHy-Q): A Cross-Cultural Adaptation and Reliability Study

Thumbnail

D1.256 - Development of multiple drug hypersensitivity after DRESS syndrome induced by piperacillin/tazobactam

Thumbnail

D1.257 - Extensive allergological workup in the management of immediate adverse drug reactions to chemotherapy- a single centre experience

Thumbnail

D1.258 - Comparison of the Negative Predictive Values of One-Day and Five-Day Drug Provocation Tests in Late-Mild and Cutaneous Beta-Lactam Allergies in Children

Thumbnail

D1.260 - Hypersensitivity to Iodinated Contrast Media: Diagnostic Evaluation and Re-exposure Outcomes

Thumbnail

D1.248 - Perioperative hypersensitivity reaction (POH) with tranexamic acid: study of 2 cases

Thumbnail

D1.249 - Improving inpatient antimicrobial stewardship through single dose oral amoxicillin challenge among penicillin allergic veterans

Thumbnail

D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab

Thumbnail

D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab

Thumbnail

D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis

Thumbnail

D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic

Thumbnail

D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates

Thumbnail

D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab

Thumbnail

D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results